Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease

Plastic and Reconstructive Surgery

Volumn 112, Issue 5, 2003, Pages 1279-1286

  Ulrich, Dietmar ^a   Hrynyschyn, Klaus ^b   Pallua, Norbert ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CARPAL TUNNEL SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DUPUYTREN CONTRACTURE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RANK SUM TEST; BLOOD; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED;

AGED; DUPUYTREN'S CONTRACTURE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 0141939335     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PRS.0000081462.40448.49     Document Type: Article

References (29)

1. Chiu, H. F., and McFarlane, R. M. Pathogenesis of Dupuytren's contracture: A correlative clinical-pathological study. J. Hand Surg. (Am.) 3: 1, 1978.
2. Badalamente, M. A., Stern, L., and Hurst, L. C. The pathogenesis of Dupuytren's contracture: Contractile mechanisms of the myofibroblasts. J. Hand Surg. (Am.) 8: 235, 1983.
3. Murrell, G. A. C., and Hueston, J. T. Aetiology of Dupuytren's contracture. Aust. N. Z. J. Surg. 60: 247, 1990.
4. Burge, P., Hoy, G., Regan, P., and Milne, R. Smoking, alcohol and the risk of Dupuytren's contracture. J. Bone Joint Surg. (Br.) 79: 206, 1997.
5. Ling, R. S. M. The genetic factors in Dupuytren's disease. J. Bone Joint Surg. (Br.) 45: 709, 1963.
6. Kloen, P. New insights in the development of Dupuytren's contracture: A review. Br. J. Plast. Surg. 52: 629, 1999.
7. Baird, K. S., Crossan, J. F., and Ralston, S. H. Abnormal growth factor and cytokine expression in Dupuytren's contracture. J. Clin. Pathol. 46: 425, 1993.
8. Hueston, J. T., and Murrell, G. A. Cell-controlling factors in Dupuytren's contracture. Ann. Chir. Main Memb. Super. 9: 135, 1990.
9. McFarlane, R. M. The current status of Dupuytren's disease. J. Hand Ther. 8: 181, 1995.
10. Liu, B., and Connolly, M. K. The pathogenesis of cutaneus fibrosis. Semin. Cutan. Med. Surg. 17: 3, 1998.
11. Reynolds, J.J. Collagenases and tissue inhibitors of metalloproteinases: A functional balance in tissue degradation. Oral Dis. 2: 70, 1996.
12. Ulrich, D., Noah, E. M., von Heimburg, D., and Pallua, N. TIMP-1, MMP-2, -9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma. Plast. Reconstr. Surg. 111: 1423, 2003.
13. Massova, I., Kotra, L. P., Fridman, R., and Mobashery, S. Matrix metalloproteinases: Structures, evolution, and diversification. F.A.S.E.B. J. 12: 1075, 1998.
14. Ravanti, L., and Kahari, V. M. Matrix metalloproteinases in wound repair. Int. J. Mol. Med. 6: 391, 2000.
15. Brew, K., Dinakarpandian, D., and Nagase, H. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim. Biophys. Acta 1477: 267, 2002.
16. Hutchinson, J. W., Tierney, G. M., Parsons, S. L., and Davis, T. R. C. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J. Bone Joint Surg. (Br.) 80: 907, 1998.
17. Luck, J. V. Dupuytren's contracture. J. Bone Joint Surg. (Am.) 41: 635, 1959.
18. Rumalla, V. K., and Borah, G. L. Cytokines, growth factors, and plastic surgery. Plast. Reconstr. Surg. 108: 719, 2001.
19. Ramadori, G., Knittel, T., and Saile, B. Fibrosis and altered matrix synthesis. Digestion 59: 372, 1998.
20. Arthur, M. J. P. Fibrosis and altered matrix degradation. Digestion 59: 376, 1998.
21. Eddy, A. A. Molecular basis of renal fibrosis. Pediatr. Nephrol. 15: 290, 2000.
22. Lichtinghagen, R., Michels, D., Heberkorn, C. I., et al. Matrix metalloproteinase MMP-2, MMP-7, and tissue inhibitor of metalloproteinase are closely related to fibroproliferative process in the liver during chronic hepatitis C. J. Hepatol. 34: 239, 2001.
23. Jackson, D. S. Development of fibrosis: Cell proliferation and collagen-biosynthesis. Ann. Rheum. Dis. 36 (Suppl.): 2, 1977.
24. Saito, S., Trovato, M., You, R., et al. Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase 1 in chronic venous insufficiency. J. Vasc. Surg. 34: 930, 2001.
25. Belotti, D., Paganoni, P., and Giavazzi, R. MMP inhibitors: Experimental and clinical studies. Int. J. Biol. Markers 14: 232, 1999.
26. Bunker, T. D., and Anthony, P. P. The pathology of frozen shoulder: A Dupuytren-like disease. J. Bone Joint Surg. (Br.) 77: 677, 1995.
27. Messina, A., and Messina, J. The continuous elongation treatment by the TEC device for severe Dupuytren's contracture of the fingers. Plast. Reconstr. Surg. 92: 84, 1995.
28. Bailey, A. J., Tarlton, J. F., Van der SteppenJ., Sims, T. J., and Messina, A. The continuous elongation technique for severe Dupuytren's disease: A biochemical mechanism. J. Hand Surg. (Br.) 19: 522, 1994.
29. Tarlton, J. F., Meagher, P., Brown, R. A., McGrouther, D. A., Bailey, A. J., and Afoke, A. Mechanical stress in vitro induces increased expression of MMPs 2 and 9 in excised Dupuytren's disease tissue. J. Hand Surg. (Br.) 23: 297, 1998.